Leuven

• A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting
  2023-509175-16-00 5 2025-10-14 Sickle cell disease
• A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting
  2024-514974-39-00 5 2025-10-10 Developmental and Epileptic Encephalopathies (DEEs)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A clinical study of MK-2214 in people with Alzheimer’s disease (MK-2214-004) Recruiting
  2024-519190-19-00 4 2025-10-03 Alzheimer’s Disease
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• A study to investigate efficacy and safety of brivekimig in participants with Crohn’s disease Recruiting
  2024-517016-30-00 4 2025-09-26 Crohn’s disease
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• Dose-Selection, Safety and Efficacy Study with Open-Label Extension of Choline Chloride for Injection in Adolescent and Adult Patients with … Recruiting
  2024-519496-26-00 10 2025-09-25 Intestinal Failure
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutec … Recruiting
  2024-518015-19-00 4 2025-09-24 Colorectal Cancer
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MM … Recruiting
  2024-511993-55-00 4 2025-09-18 bile acid diarrhoea (BAD)
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs … Recruiting
  2024-518586-10-00 10 2025-09-18 Non-Squamous Non-Small Cell Lung Cancer
• A phase 2 study of the effectiveness of golcadomide (CC-99282) for patients with large B-cell lymphoma in the brain Recruiting
  2024-517051-12-00 4 2025-09-16 Relapsed primary large B-cel lymphoma of the central nervous system
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy … Recruiting
  2024-511178-66-00 5 2025-09-12 Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer
• An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients wi … Recruiting
  2024-514970-27-00 5 2025-09-03 Non-Dystrophic Myotonias (NDM)
• Model-informed precision dosing during infliximab rescue therapy for patients with steroid-refractory acute severe ulcerative colitis: an ex … Recruiting
  2023-503509-12-00 6 2025-09-01 Acute severe ulcerative colitis

Showing 289–312 of 1,145 trials